References

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

10.1056/nejmoa2034577 · 2020 · External reference

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK Kingdom

10.1016/s0140-6736(20)32661-1 · 2021 · External reference

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

10.1056/nejmoa2035389 · 2021 · External reference

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

10.1001/jama.2021.8565 · 2021 · External reference

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

10.1016/s0140-6736(21)00234-8 · 2021 · External reference

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

10.1016/s0140-6736(21)00432-3 · 2021 · External reference

Will covid-19 vaccines save lives? Current trials aren’t designed to tell us

2020 · External reference

Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study

10.1016/s0140-6736(22)00011-3 · 2022 · External reference

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

10.1056/nejmoa2107715 · 2021 · External reference

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

10.1056/nejmoa2105290 · 2021 · External reference

Unresolved reference

External reference

Impact of the Sinopharm’s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)

10.1016/j.vaccine.2022.02.039 · 2022 · External reference

BBIP-CorV vaccine effectiveness for preventing infection and death of health workers, Peru 2021

2023 · External reference

Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021

10.1016/j.vaccine.2022.03.067 · 2022 · External reference

Effectiveness and waning of protection with different SARS-CoV-2 primary and booster vaccines during the Delta pandemic wave in 2021 in Hungary (HUN-VE 3 study)

2022 · External reference

Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence-China, 2021

10.46234/ccdcw2022.009 · 2022 · External reference

Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates

10.1038/s41467-022-30835-1 · 2022 · External reference

Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study

10.1016/j.cmi.2021.11.011 · 2022 · External reference

Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco. 2022

10.1371/journal.pone.0278546 · 2022 · External reference

Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco

10.1186/s12889-022-14016-9 · 2022 · External reference

Effectiveness and safety of inactivated SARS-CoV2 vaccine (BBIBP-CorV) among healthcare workers: A seven-month follow-up study at fifteen hospitals

10.3390/vaccines11050892 · 2023 · External reference

Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario

10.1038/s41564-021-01053-0 · 2022 · External reference

First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India

10.1136/bmjgh-2021-008271 · 2022 · External reference

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

10.1016/s0140-6736(21)00677-2 · 2021 · External reference

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

10.1136/bmj.n1088 · 2021 · External reference

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

10.1056/nejmoa2102214 · 2021 · External reference

Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern

2022 · External reference

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

10.1038/s41586-021-03398-2 · 2021 · External reference